Midgard Science

Labs / ADME, DMPK & toxicology

Manhattan BioSolutions

New York, NY, United States · manhattanbiosolutions.com

Manhattan BioSolutions develops precision biologic therapies, with a focus on next-generation antibody-drug conjugates for advanced cancers. It collaborates with academic researchers and other partners and is based in New York City.

Their website has a general contact form; we send your quote request through it.

What they offer

  • Antibody-drug conjugate (ADC) platform development

    Develops next-generation ADCs with custom linker chemistry and payload design for targeted cancer therapy.

  • Legumain-cleavable linker-payload systems

    Creates linker systems that remain stable in circulation and activate in the tumor microenvironment for localized payload release.

  • TOP1i ADC payload development

    Optimizes topoisomerase I inhibitor payloads derived from exatecan for ADC applications.

  • Taxoid (TxD) ADC payload development

    Advances taxoid-based payloads for antibody-drug conjugates targeting solid tumors.

  • Pan-RNA degrader technology

    Develops pan-RNA degrader technologies intended to selectively degrade RNA in tumors and their microenvironment.

  • Antibody engineering and bioconjugation

    Combines antibody engineering, linker chemistry, and bioconjugation to build targeted biologic agents.

What they work on

Modalities
Antibody, ADC, Peptide
Species and models
solid tumor xenograft models, ovarian cancer models, prostate cancer models, non-small cell lung cancer models, colon cancer models
Assays and studies
high throughput FRET-based screen
Therapeutic areas
oncology, advanced cancers, solid tumors, pediatric cancers, inflammatory responses, age-related diseases
Sites
New York City, United States

Similar labs. Aurigene Pharmaceutical Services, Sparx BIO, Bioneeds, Sai Life

Found in a contract services directory. Listing built from manhattanbiosolutions.com. Work here? Claim this listing.

Manhattan BioSolutions · Midgard Science